"The question for the FDA is whether there should be a general warning, particularly for patients who are at high risk of cardiovascular disease," the doctor said. "
to the risk of heart attack or stroke," he said in an interview. "
It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.
With Vioxx, researchers had been warning about the drug's possible cardiovascular risks since 2000, only a year after it was approved by the FDA.
